Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Cash & Equivalents

Cash & Equivalents at other companies

Alkermes logo
AlkermesALKS
$351.55M-12.1%
JAN
Janus Living JAN
$10.52M-2.7%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×—
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's cash & equivalents?
Indivior Pharmaceuticals, Inc. (INDV) reported cash & equivalents of $175M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's cash & equivalents changed year-over-year?
Indivior Pharmaceuticals, Inc. 's cash & equivalents decreased by 53.0% year-over-year, from $372M to $175M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's cash & equivalents?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's cash & equivalents has grown at a -21.4% compound annual growth rate (CAGR), from $316M to $195M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.